RCKT
Rocket Pharmaceuticals Inc

3,088
Loading...
Loading...
News
all
press releases
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients
The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys.
Stocktwits·1mo ago
News Placeholder
Why Is Rocket Pharma Stock Up 25% Pre-Market Today?
The U.S. Food and Drug Administration has lifted the clinical hold on the company’s mid-stage study of RP-A501 for the treatment of Danon disease.
Stocktwits·1mo ago
News Placeholder
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
Zacks·3mo ago
News Placeholder
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.
Zacks·3mo ago
News Placeholder
RCKT Stock Tanks on Patient Death in Danon Disease Study
Zacks·4mo ago
News Placeholder
Booz Allen, FreshPet, Rocket Pharma Downgraded, While Vail Resorts And FICO Get An Upgrade – Top Wall Street Analyst Calls Today
State Street received an upgrade from Truist, raising the stock to ‘Buy’ from ‘Hold’ and increasing its price target to $112 from $85.
Stocktwits·4mo ago
News Placeholder
Patient Death In Rocket Pharma Trial Triggers Downgrades, But Retail Traders Bet Big On Strong Recovery
Message volume on Stocktwits spiked to ‘extremely high’ levels, and the ticker added 20% more watchers.
Stocktwits·4mo ago
News Placeholder
Rocket Pharmaceuticals Stock Drops Pre-Market After FDA Pauses Gene Therapy Trial Over Patient Death: Retail Turns Bullish
Rocket Pharmaceuticals said that it is working with the FDA to ensure safety of all study patients and resume the trial “as expeditiously as possible."
Stocktwits·4mo ago
News Placeholder
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...
Business Wire·9mo ago

Latest RCKT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.